NICE confirms guidance on first-line MabThera in CLL
This article was originally published in Scrip
Executive Summary
Roche's MabThera (rituximab) has been recommended for use in the national health service in England and Wales as a first-line treatment option for patients with chronic lymphocytic leukaemia, in combination with fludarabine and cyclophosphamide chemotherapy.